Nura Bio Secures $73.8M in Series B Funding for Advancement of Clinical-Stage SARM1 Inhibitor Programs

Nura Bio secures $73.8M in Series B financing, led by The Column Group, for the advancement of its clinical-stage SARM1 inhibitor programs.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here